IC
NKTR icon

Ikarian Capital’s Nektar Therapeutics NKTR Stock Holding History

Ikarian Capital’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-105,302
Closed -$1.07M – 173
2025
Q1 		$1.07M Sell
105,302
-29,967
-22% -$392K 0.13% 97
2024
Q4 		$1.89M Buy
135,269
+47,775
+55% +$843K 0.26% 83
2024
Q3 		$1.71M Hold
87,494
– – 0.24% 76
2024
Q2 		$1.63M Buy
+87,494
New +$1.84M 0.28% 60

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ikarian Capital's NKTR Position: Q2 2025 in Review

Ikarian Capital sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 105,302 shares — an estimated $1.07M sold.

Ikarian Capital first reported a position in NKTR in Q2 2024 and held it in 4 quarters. The position peaked at $1.89M in Q4 2024. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.

  • Ikarian Capital reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Ikarian Capital sold 105,302 Nektar Therapeutics shares in Q2 2025, an estimated $1.07M.
  • Ikarian Capital first reported a position in Nektar Therapeutics in Q2 2024 and held it in 4 quarters.
  • Ikarian Capital's Nektar Therapeutics position peaked at $1.89M in Q4 2024.
  • 109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.

Based on Ikarian Capital's 13F filing for Q2 2025, filed 14 Aug 2025.